Development of a novel vaccinia-neutralization assay based on reporter-gene expression

Journal of Infectious Diseases

Volumn 188, Issue 3, 2003, Pages 440-448

  Manischewitz, Jody ^a   King, Lisa R ^a   Bleckwenn, Nicole A ^b,e,f   Shiloach, Joseph ^b   Taffs, Rolf ^a   Merchlinsky, Michael ^a   Eller, Nancy ^a   Mikolajczyk, Malgorzata G ^a   Clanton, David J ^c   Monath, Thomas ^d   Weltzin, Richard A ^d   Scott, Dorothy E ^a   Golding, Hana ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c DynPort Vaccine Company LLC   (United States)

^d Acambis   (United States)

^e UNIVERSITY OF MARYLAND   (United States)

^f UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; IMMUNOGLOBULIN; SMALLPOX VACCINE; UNCLASSIFIED DRUG; VACCINIA ANTIBODY;

ARTICLE; ASSAY; AUTOMATION; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; HELA CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LABORATORY TEST; PLAQUE REDUCTION NEUTRALIZATION TEST; PRIORITY JOURNAL; REPORTER GENE; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STANDARD; VACCINIA VIRUS; VIRUS NEUTRALIZATION; VIRUS NEUTRALIZATION ASSAY;

ANIMALS; ANTIBODIES, VIRAL; BETA-GALACTOSIDASE; CELL LINE; GENE EXPRESSION; GENES, REPORTER; HUMANS; IMMUNOGLOBULINS; NEUTRALIZATION TESTS; RECOMBINATION, GENETIC; SENSITIVITY AND SPECIFICITY; VACCINIA VIRUS;

EID: 0042157260     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/376557     Document Type: Article

References (17)

1. Henderson DA. The looming threat of bioterrorism. Science 1999; 283:1279-82.
2. Henderson DA. Smallpox: clinical and epidemiologic features. Emerg Infect Dis 1999; 5:537-9.
3. Henderson DA, Fenner F. Recent events and observations pertaining to smallpox virus destruction in 2002. Clin Infect Dis 2001; 33:1057-9.
4. Henderson DA, Inglesby TV, Bartlett JG, et al. Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 1999; 281:2127-37.
5. Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968. N Engl J Med 1969; 281:1201-8.
6. Goldstein JA, Neff JM, Lane JM, Koplan JP. Smallpox vaccination reactions, prophylaxis, and therapy of complications. Pediatrics 1975; 55:342-7.
7. Katz JB. The effect of the virus-serum incubation period upon vaccinia virus serum neutralization titers. J Biol Stand 1987; 15:389-92.
8. Mack TM, Noble J Jr, Thomas DB. A prospective study of serum antibody and protection against smallpox. Am J Trop Med Hyg 1972; 21:214-8.
9. Paoletti E. Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci USA 1996; 93:11349-53.
10. Chakrabarti S, Sisler JR, Moss B. Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 1997; 23:1094-7.
11. Frey SE, et al. Dose-related effects of smallpox vaccine. N Engl J Med 2002; 346:1275-80.
12. Payne LG. Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia. J Gen Virol 1980; 50:89-100.
13. Roos N, Cyrklaff M, Cudmore S, Blasco R, Krijinse-Locker J, Griffiths G. A novel immunogold cryoelectron microscopic approach to investigate the structure of the intracellular and extracellular forms of vaccinia virus. Embo J 1996; 15:2343-55.
14. McClain DJ, Harrison S, Yeager CL, et al. Immunologic responses to vaccinia vaccines administered by different parenteral routes. J Infect Dis 1997; 175:756-63.
15. Hollinshead M, Rodger G, Van Eijl H, et al. Vaccinia virus utilizes microtubules for movement to the cell surface. J Cell Biol 2001; 154:389-402.
16. Ramirez JC, Gherardi MM, Esteban M. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J Virol 2000; 74:923-33.
17. Edghill-Smith Y, Venzon D, Karpova T, et al. Modeling a safer small-pox-vaccination regimen for patients with AIDS in immune-compromised macaques. J Infect Dis (in press).